{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T23:33:23Z","timestamp":1778888003221,"version":"3.51.4"},"reference-count":78,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Curr"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:p>This review summarizes content presented at the Pediatric State of the Art Symposium held during the American Epilepsy Society's annual meeting in December 2024. The symposium focused on Lennox-Gastaut syndrome (LGS), a severe developmental and epileptic encephalopathy that emerges in childhood. Despite its diverse etiologies, LGS is defined by a convergent constellation of electroclinical features: multiple seizure types including tonic seizures, slow spike-wave and generalized paroxysmal fast activity on EEG, and intellectual disability. LGS is almost always refractory to available therapies and accounts for substantial costs\u2014in healthcare spending and in quality of life for affected individuals, their families, and caregivers. The symposium highlighted recent breakthroughs in research, clinical care, and outcome measurement that have positioned the clinical, scientific, and patient advocacy communities to usher in a new, more hopeful era of treatment and prevention.<\/jats:p>","DOI":"10.1177\/15357597251321926","type":"journal-article","created":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T17:18:25Z","timestamp":1742923105000},"page":"236-243","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Mobilizing a New Era in Lennox-Gastaut Syndrome Treatment and Prevention"],"prefix":"10.1177","volume":"25","author":[{"given":"Aaron E.L.","family":"Warren","sequence":"first","affiliation":[{"name":"Mass General Brigham"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9313-1541","authenticated-orcid":false,"given":"Anup D.","family":"Patel","sequence":"additional","affiliation":[{"name":"Nationwide Children's Hospital"},{"name":"Nationwide Children's Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7345-4829","authenticated-orcid":false,"given":"J.","family":"Helen Cross","sequence":"additional","affiliation":[{"name":"Developmental Neurosciences Department, UCL NIHR BRC, Great Ormond Street Institute of Child Health, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dave F.","family":"Clarke","sequence":"additional","affiliation":[{"name":"Dell Medical School, University of Texas at Austin"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda J.","family":"Dalic","sequence":"additional","affiliation":[{"name":"Austin Health"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary M.","family":"Grinspan","sequence":"additional","affiliation":[{"name":"Weill Cornell Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabrielle","family":"Conecker","sequence":"additional","affiliation":[{"name":"The Inchstone Project, a Project of Decoding Developmental Epilepsies, Washington, DC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9214-2991","authenticated-orcid":false,"given":"Juliet K.","family":"Knowles","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,3,25]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneurpsyc.1939.02270180039002"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.5.4.626"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.1966.tb06263.x"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.52211"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17241"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/epi.14569"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2011.03177.x"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1996.tb01821.x"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1989.tb05316.x"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2024.2323568"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2014.00225"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12682"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007775"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3182a08f6a"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/epi.13720"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2018-0449"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3003544"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.3651"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26280"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26368"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16851"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2022.10.020"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/amiajnl-2013-001926"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(08)70292-8"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcaa028"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24098458"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41593-022-01052-2"},{"issue":"3","key":"e_1_3_2_29_2","first-page":"669","article-title":"Clemizole and modulators of serotonin signalling suppress seizures in Dravet syndrome","volume":"140","author":"Griffin A","year":"2017","unstructured":"Griffin A, Hamling KR, Knupp K, Hong S, Lee LP, Baraban SC. Clemizole and modulators of serotonin signalling suppress seizures in Dravet syndrome. Brain. 2017;140(3):669-683.","journal-title":"Brain"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-021-02221-y"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.110172"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2023.05.018"},{"issue":"4","key":"e_1_3_2_33_2","article-title":"Anti-seizure medications for Lennox-Gastaut syndrome","volume":"4","author":"Brigo F","year":"2021","unstructured":"Brigo F, Jones K, Eltze C, Matricardi S. Anti-seizure medications for Lennox-Gastaut syndrome. Cochrane Database Syst Rev. 2021;4(4):CD003277.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"e_1_3_2_34_2","article-title":"Treatment of Lennox-Gastaut syndrome","author":"Hancock E","year":"2003","unstructured":"Hancock E, Cross H. Treatment of Lennox-Gastaut syndrome. Cochrane Database Syst Rev. 2003(3):CD003277.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003277.pub2"},{"issue":"2","key":"e_1_3_2_36_2","article-title":"Treatment of Lennox-Gastaut syndrome","volume":"2013","author":"Hancock EC","year":"2013","unstructured":"Hancock EC, Cross JH. Treatment of Lennox-Gastaut syndrome. Cochrane Database Syst Rev. 2013;2013(2):CD003277.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2017.00505"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2020.107146"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2022.07.004"},{"key":"e_1_3_2_40_2","article-title":"Refining management strategies for Lennox-Gastaut syndrome: updated algorithms and practical approaches","author":"Auvin S","unstructured":"Auvin S, Arzimanoglou A, Falip M, Striano P, Cross JH. Refining management strategies for Lennox-Gastaut syndrome: updated algorithms and practical approaches. Epilepsia Open. 2025;10(1):85-106. doi:10.1002\/epi4.13075","journal-title":"Epilepsia Open"},{"issue":"6","key":"e_1_3_2_41_2","first-page":"217","article-title":"Lennox-Gestaut syndrome: Therapeutic aspects","volume":"59","author":"Pisani F","year":"1989","unstructured":"Pisani F, Oteri G, Di Perri R. Lennox-Gestaut syndrome: Therapeutic aspects. Riv Neurol. 1989;59(6):217-219.","journal-title":"Riv Neurol"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200022060-00005"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004691-200311000-00005"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(08)70092-9"},{"issue":"6","key":"e_1_3_2_45_2","article-title":"Ketogenic diets for drug-resistant epilepsy","volume":"6","author":"Martin-McGill KJ","year":"2020","unstructured":"Martin-McGill KJ, Bresnahan R, Levy RG, Cooper PN. Ketogenic diets for drug-resistant epilepsy. Cochrane Database Syst Rev. 2020;6(6):CD001903.","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2016.11.003"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-8749.2012.04233.x"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.3390\/nu14234977"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1111\/epi.12742"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000208087"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2009-0566"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17350"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2009.02397.x"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1684\/epd.2021.1253"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2023.10.011"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1992.tb02192.x"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1993.tb02134.x"},{"key":"e_1_3_2_58_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2006.00593.x"},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1111\/epi.16895"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2022.07.014"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nec.2023.09.002"},{"key":"e_1_3_2_62_2","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcae161"},{"key":"e_1_3_2_63_2","doi-asserted-by":"publisher","DOI":"10.3171\/2022.2.JNS212237"},{"key":"e_1_3_2_64_2","doi-asserted-by":"publisher","DOI":"10.1111\/epi.17414"},{"key":"e_1_3_2_65_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26956"},{"key":"e_1_3_2_66_2","doi-asserted-by":"publisher","DOI":"10.1177\/08830738211000514"},{"key":"e_1_3_2_67_2","doi-asserted-by":"crossref","unstructured":"Deering L Nelson A Yozawitz E et al. A multicenter retrospective observational cohort study of seizure freedom before Lennox-Gastaut syndrome (the \u201cgap\u201d). opportunities for prevention. medRxiv 2024.","DOI":"10.1101\/2024.12.03.24318373"},{"key":"e_1_3_2_68_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.25956"},{"key":"e_1_3_2_69_2","article-title":"Early treatment with Vigabatrin does not decrease focal seizures or improve cognition in tuberous sclerosis complex: the PREVeNT trial","author":"Bebin EM","unstructured":"Bebin EM, Peters JM, Porter BE, et al. Early treatment with Vigabatrin does not decrease focal seizures or improve cognition in tuberous sclerosis complex: the PREVeNT trial. Ann Neurol. 2023;95(1):15-26.","journal-title":"Ann Neurol"},{"key":"e_1_3_2_70_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012511"},{"key":"e_1_3_2_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00409-X"},{"key":"e_1_3_2_72_2","doi-asserted-by":"publisher","DOI":"10.1684\/epd.2021.1247"},{"key":"e_1_3_2_73_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2021.106847"},{"issue":"3","key":"e_1_3_2_74_2","first-page":"173","article-title":"Intravenous methylprednisolone pulse therapy for children with epileptic encephalopathy","volume":"30","author":"Pera MC","year":"2015","unstructured":"Pera MC, Randazzo G, Masnada S, et al. Intravenous methylprednisolone pulse therapy for children with epileptic encephalopathy. Funct Neurol. 2015;30(3):173-179.","journal-title":"Funct Neurol"},{"key":"e_1_3_2_75_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2013.12.015"},{"key":"e_1_3_2_76_2","doi-asserted-by":"crossref","DOI":"10.1684\/epd.2011.0409","article-title":"Evolution and management of Lennox-Gastaut syndrome through adolescence and into adulthood: are seizures always the primary issue?","volume":"13","author":"Kerr M","year":"2011","unstructured":"Kerr M, Kluger G, Philip S. Evolution and management of Lennox-Gastaut syndrome through adolescence and into adulthood: are seizures always the primary issue? Epileptic Disord. 2011;13(Suppl 1):S15-S26.","journal-title":"Epileptic Disord"},{"key":"e_1_3_2_77_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2023.109451"},{"key":"e_1_3_2_78_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2024.109975"},{"key":"e_1_3_2_79_2","unstructured":"Perkins School for the Blind. The current state of CVI: a hidden epidemic. 2023. https:\/\/www.perkins.org\/wp-content\/uploads\/2023\/09\/CVI_Whitepaper_FINAL.pdf"}],"container-title":["Epilepsy Currents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15357597251321926","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/15357597251321926","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/15357597251321926","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T20:32:30Z","timestamp":1777408350000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/15357597251321926"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,25]]},"references-count":78,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1177\/15357597251321926"],"URL":"https:\/\/doi.org\/10.1177\/15357597251321926","relation":{},"ISSN":["1535-7597","1535-7511"],"issn-type":[{"value":"1535-7597","type":"print"},{"value":"1535-7511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,25]]}}}